Cingulate Therapeutics, LLC (CTx) is a privately held, clinical stage biopharmaceutical company focused on the development of innovative new products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). Cingulate is developing two (2) proprietary, first-line medications, CTX-1301 (Dexmethylphenidate) and CTX-1302 (Dextroamphetamine), via the accelerated 505 (b)(2) regulatory pathway for the treatment of ADHD seeking indications for all patient segments: children, adolescents and adults.
